[
  {
    "ts": null,
    "headline": "Should You Buy More Shares of Your Loser Stocks?",
    "summary": "Intel, Disney and 3 others have struggled the last 5 years. Should long-time investors double down?",
    "url": "https://finnhub.io/api/news?id=41c8b6d764d34ca971026bfb54378c06dede2757c72272505b150373cdb9fe77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732750980,
      "headline": "Should You Buy More Shares of Your Loser Stocks?",
      "id": 131675607,
      "image": "https://media.zenfs.com/en/zacks.com/ffea6ebd26f5d710d2792ac7db03dab2",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Intel, Disney and 3 others have struggled the last 5 years. Should long-time investors double down?",
      "url": "https://finnhub.io/api/news?id=41c8b6d764d34ca971026bfb54378c06dede2757c72272505b150373cdb9fe77"
    }
  },
  {
    "ts": null,
    "headline": "A Short Lesson in Drug Competition",
    "summary": "A Short Lesson in Drug Competition",
    "url": "https://finnhub.io/api/news?id=191662efa5c62e9dabbc8527e201576b61bcf4f878887e51061820c73e0f1f2a",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732732920,
      "headline": "A Short Lesson in Drug Competition",
      "id": 131777330,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "A Short Lesson in Drug Competition",
      "url": "https://finnhub.io/api/news?id=191662efa5c62e9dabbc8527e201576b61bcf4f878887e51061820c73e0f1f2a"
    }
  },
  {
    "ts": null,
    "headline": "ACAD Signs License Deal With Saniona for Rights to Neurology Drug",
    "summary": "Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.",
    "url": "https://finnhub.io/api/news?id=d8b7fdac6c85ee1114a72a532875823cc6ccf7627077360ca28b126db6d72f52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732719960,
      "headline": "ACAD Signs License Deal With Saniona for Rights to Neurology Drug",
      "id": 131668614,
      "image": "https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.",
      "url": "https://finnhub.io/api/news?id=d8b7fdac6c85ee1114a72a532875823cc6ccf7627077360ca28b126db6d72f52"
    }
  },
  {
    "ts": null,
    "headline": "Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?",
    "summary": "Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales.  In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion.  It might not feel like it when you pay the bill, but prescription drugs give healthcare systems a tremendous return on their investment.",
    "url": "https://finnhub.io/api/news?id=85ed599d363bcd0533029f5b25548bddde9cc2bf699e52ba997bf28b0265a6b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732703460,
      "headline": "Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?",
      "id": 131668615,
      "image": "https://g.foolcdn.com/editorial/images/798910/wall-street-analyst-getty.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales.  In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion.  It might not feel like it when you pay the bill, but prescription drugs give healthcare systems a tremendous return on their investment.",
      "url": "https://finnhub.io/api/news?id=85ed599d363bcd0533029f5b25548bddde9cc2bf699e52ba997bf28b0265a6b7"
    }
  },
  {
    "ts": null,
    "headline": "High-Quality Dividend Growth Stocks Near 52-Week Lows: Pfizer Is Fun",
    "summary": "Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=aefa9c136736466dbcfb8f6fdaa159ad086d5bef4857662d5a31239520fad9a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732688207,
      "headline": "High-Quality Dividend Growth Stocks Near 52-Week Lows: Pfizer Is Fun",
      "id": 131663750,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/983308646/image_983308646.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=aefa9c136736466dbcfb8f6fdaa159ad086d5bef4857662d5a31239520fad9a9"
    }
  }
]